Can a shot keep hepatitis b away after 'Cure'? new trial aims to find out

NCT ID NCT07328711

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether hepatitis B immunoglobulin (HBIG) can help people with chronic hepatitis B stay virus-free after they've cleared the surface antigen (a key sign of cure). Researchers will give HBIG shots to 132 participants who already cleared the virus with standard therapy, then check if the virus stays gone for 48 weeks. The goal is to reduce relapse and find better ways to achieve a lasting cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hepatitis B immunoglobulin (HBIG)
What this could lead to: If it works, this could help people with chronic hepatitis B stay virus-free after initial clearance, reducing the chance of relapse and moving closer to a complete cure.
What could go wrong: This is a very early, small study (132 people) with no guarantee of success. HBIG is a temporary boost, not a permanent fix, and may not prevent relapse in the long run.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPAITITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPAITITIS B

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.